These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 32929383)

  • 1. Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma.
    Park C; Na KJ; Choi H; Ock CY; Ha S; Kim M; Park S; Keam B; Kim TM; Paeng JC; Park IK; Kang CH; Kim DW; Cheon GJ; Kang KW; Kim YT; Heo DS
    Theranostics; 2020; 10(23):10838-10848. PubMed ID: 32929383
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
    Front Immunol; 2021; 12():677169. PubMed ID: 34354701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.
    Wang Q; Li M; Yang M; Yang Y; Song F; Zhang W; Li X; Chen K
    Aging (Albany NY); 2020 Feb; 12(4):3312-3339. PubMed ID: 32091408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients.
    Shi R; Bao X; Unger K; Sun J; Lu S; Manapov F; Wang X; Belka C; Li M
    Theranostics; 2021; 11(10):5061-5076. PubMed ID: 33754044
    [No Abstract]   [Full Text] [Related]  

  • 6. Seven interferon gamma response genes serve as a prognostic risk signature that correlates with immune infiltration in lung adenocarcinoma.
    Yao B; Wang L; Wang H; Bao J; Li Q; Yu F; Zhu W; Zhang L; Li W; Gu Z; Fei K; Zhang P; Zhang F; Huang X
    Aging (Albany NY); 2021 Apr; 13(8):11381-11410. PubMed ID: 33839701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
    Chen G; Dong Z; Wu D; Chen Y
    J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P2RX7B is a new theranostic marker for lung adenocarcinoma patients.
    Benzaquen J; Dit Hreich SJ; Heeke S; Juhel T; Lalvee S; Bauwens S; Saccani S; Lenormand P; Hofman V; Butori M; Leroy S; Berthet JP; Marquette CH; Hofman P; Vouret-Craviari V
    Theranostics; 2020; 10(24):10849-10860. PubMed ID: 33042257
    [No Abstract]   [Full Text] [Related]  

  • 9. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
    Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
    Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures.
    Sui P; Liu X; Zhong C; Sha Z
    Sci Rep; 2024 May; 14(1):10873. PubMed ID: 38740918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive molecular analyses of cuproptosis-related genes with regard to prognosis, immune landscape, and response to immune checkpoint blockers in lung adenocarcinoma.
    Li R; Tong R; Zhang JL; Zhang Z; Deng M; Hou G
    J Cancer Res Clin Oncol; 2024 May; 150(5):246. PubMed ID: 38722401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCDH11X mutation as a potential biomarker for immune checkpoint therapies in lung adenocarcinoma.
    Liu M; Yang M; Zhang B; Xia S; Zhao J; Yan L; Ren Y; Guo H; Zhao J
    J Mol Med (Berl); 2024 Jul; 102(7):899-912. PubMed ID: 38739269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat shock factor 5 correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma.
    Aizemaiti R; Wu Z; Tang J; Yan H; Lv X
    Int J Med Sci; 2021; 18(2):448-458. PubMed ID: 33390814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single-cell transcriptomic analysis: Implications for distinct immunotherapy outcomes.
    Fang X; Li D; Wan S; Hu J; Zhang P; Jie D; Chen L; Jiang G; Song N
    J Gene Med; 2024 Jun; 26(6):e3694. PubMed ID: 38847309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy.
    Liao Y; He D; Wen F
    Immunogenetics; 2021 Oct; 73(5):369-380. PubMed ID: 34302518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification immunophenotyping of lung adenocarcinomas based on the tumor microenvironment.
    Tan Q; Huang Y; Deng K; Lu M; Wang L; Rong Z; Zhao W; Li S; Xu Z; Fan L; Li K; Li Z
    J Cell Biochem; 2020 Nov; 121(11):4569-4579. PubMed ID: 32030808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance of
    Zheng H; Cui Y; Li X; Du B; Li Y
    Clin Lung Cancer; 2019 Nov; 20(6):420-428. PubMed ID: 31300363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
    Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
    Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.